Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

AIM: Some retrospective studies have shown a lack of benefit of 5‐fluorouracil (5‐FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5‐FU adjuvant chemotherapy. A second objective was t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Piñol, V, Xicola, R M, Bujanda, L, Reñé, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolás‐Pérez, D, Payá, A, Alenda, C
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Group 2006
Materias:
Colorectal Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856227/
https://ncbi.nlm.nih.gov/pubmed/16299036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.073015
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares